- •DEDICATION
- •PREFACE
- •CONTRIBUTORS
- •INSTRUCTIONS TO USERS
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •generic name: Zidovudine.
- •Primary use
- •Ocular side effects
- •Systemic administration (oral or intravenous)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Amebicides
- •generic names: 1. Broxyquinoline; 2. diiodohydroxyquinoline (iodoquinol).
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Emetine hydrochloride.
- •Primary use
- •Ocular side effects
- •Inadvertent ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Anthelmintics
- •generic name: Diethylcarbamazine citrate.
- •Primary use
- •Ocular side effects
- •Local ophthalmic use or exposure – topical application
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Mepacrine hydrochloride.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Inadvertent direct ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Piperazine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Thiabendazole.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: AntibiOtics
- •generic name: Amikacin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Bacitracin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •Inadvertent orbital injection (ointment)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Chloramphenicol.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •Local ophthalmic use or exposure – intracameral injection
- •systemic side effects
- •Local ophthalmic use or exposure
- •clinical significance
- •Recommendations for topical ocular chloramphenicol
- •REFERENCES AND FURTHER READING
- •generic name: Ciprofloxacin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application
- •Systemic reactions from topical ocular medication
- •Conditional/Unclassified
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Demeclocycline; 2. doxycycline; 3. minocycline; 4. oxytetracycline; 5. tetracycline.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: filgrastim.
- •Primary use
- •Ocular side effect
- •Systemic administration – intravenous
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application
- •Systemic reactions from topical ocular medication
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Gentamicin sulfate.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •Local ophthalmic use or exposure – intravitreal or intraocular injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Kanamycin sulfate.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – subconjunctival injection
- •REFERENCES AND FURTHER READING
- •generic name: Linezolid.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •generic name: Nalidixic acid.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Neomycin.
- •Primary use
- •Ocular side effects
- •Systemic administration (neomycin powder to mucus membranes)
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Nitrofurantoin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Polymyxin B sulfate.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Sulfacetamide; 2. sulfafurazole (sulfisoxazole); 3. sulfamethizole; 4. sulfamethoxazole; 5. sulfanilamide; 6. sulfasalazine; 7. sulfathiazole.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application
- •Conditional/Unclassified
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Telithromycin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Probable
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Tobramycin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application
- •Inadvertent ocular exposure – intraocular injection
- •Inadvertent ocular exposure – subconjunctival injection
- •Inadvertent ocular exposure – ointment in anterior chamber
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Antifungal Agents
- •generic name: Amphotericin B.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – topical application or subconjunctival injection
- •Local ophthalmic use or exposure – intracameral injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Griseofulvin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES
- •Class: Antileprosy Agents
- •generic name: Clofazimine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Dapsone.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Chloroquine; 2. hydroxychloroquine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations for hydroxychloroquine
- •Recommendations for chloroquine
- •caution
- •REFERENCES AND FURTHER READING
- •generic name: Mefloquine hydrochloride.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Quinine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Antiprotozoal Agents
- •generic name: Metronidazole.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Suramin sodium.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Tryparsamide.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Antitubercular Agents
- •generic name: Cycloserine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Ethambutol.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •generic name: Ethionamide.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Isoniazid.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Rifabutin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Rifampicin.
- •Primary use
- •Systemic
- •Ophthalmic
- •Ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure (ointment)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Thioacetazone (Amithiozone).
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Analeptics
- •generic name: Gabapentin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Lamotrigine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Vigabatrin.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Benzfetamine hydrochloride; 2. amfepramone hydrochloride (diethylpropion); 3. phendimetrazine tartrate; 4. phentermine.
- •REFERENCES AND FURTHER READING
- •class: antianxiety agents
- •Generic names: 1. Alprazolam; 2. chlordiazepoxide; 3. clonazepam; 4. clorazepate dipotassium; 5. diazepam; 6. flurazepam; 7. lorazepam; 8. midazolam; 9. oxazepam; 10. temazepam; 11. triazolam.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Carisoprodol; 2. meprobamate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: anticonvulsants
- •Generic names: 1. Ethosuximide; 2. methsuximide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Ethotoin.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Phenytoin.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Ocular teratogenic effects (fetal hydantoin syndrome)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Sodium valproate; 2. valproate semisodium; 3. valproic acid.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Topiramate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Ocular teratogenic effects
- •clinical significance
- •Recommendations (Fraunfelder, Fraunfelder and Keates)
- •REFERENCES AND FURTHER READING
- •Generic name: Zonisamide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: antidepressants
- •Generic names: 1. Amitriptyline; 2. desipramine hydrochloride; 3. nortriptyline hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Amoxapine; 2. clomipramine hydrochloride; 3. doxepin hydrochloride; 4. trimipramine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Carbamazepine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Citalopram hydrobromide; 2. fluoxetine hydrochloride; 3. fluvoxamine maleate; 4. paroxetine hydrochloride; 5. sertaline.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Isocarboxazid; 2. phenelzine; 3. tranylcypromine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: Maprotiline.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Methylphenidate hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration – oral
- •Systemic administration – intravenous
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Trazodone.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: antipsycHotic agents
- •Generic names: 1. Chlorpromazine; 2. fluphenazine; 3. perphenazine; 4. prochlorperazine; 5. promethazine; 6. thiethylperazine; 7. thioridazine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Droperidol; 2. haloperidol.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Lithium carbonate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Loxapine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Pimozide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Quetiapine fumarate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic names: Tiotixene.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: Psychedelic agents
- •Generic names: 1. Dronabinol (tetrahydrocannabinol, THC); 2. hashish; 3. marihuana (marijuana).
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Lysergic acid diethylamide (LSD), lysergide; 2. mescaline; 3. psilocybin.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Topical ocular application – liquid LSD
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Phencyclidine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: Sedatives and Hypnotics
- •Generic names: 1. Amobarbital; 2. butalbital; 3. methohexital; 4. methylphenobarbital (mephobarbital); 5. pentobarbital; 6. phenobarbital; 7. primidone; 8. secbutabarbital; 9. secobarbital.
- •Primary use
- •ocular side effects
- •Systemic administration (Primarily excessive dosage or chronic use)
- •Ocular teratogenic effects (primidone)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Chloral hydrate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: agents used to treat gout
- •Generic name: Allopurinol.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name: Colchicine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Inadvertent ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: antirheumatic agents
- •Generic name: 1. Adalimumab; 2. etanercept; 3. infliximab.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Auranofin; 2. aurothioglucose; 3. sodium aurothiomalate (gold sodium thiomalate).
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Celecoxib; 2. etolodac; 3. nimesulide; 4. rofecoxib; 5. valdecoxib.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Fenoprofen calcium.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Flurbiprofen.
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Ibuprofen.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Indometacin (indomethacin).
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure - topical ocular
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Ketoprofen.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: naproxen.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Piroxicam.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: Mild analgesics
- •Generic names: Aspirin (acetylsalicylic acid).
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Codeine; 2. dextropropoxyphene.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: Paracetamol (acetaminophen).
- •Primary use
- •ocular side effects
- •Systemic administration
- •Possible
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: narcotic antagonists
- •Generic names: 1. naloxone hydrochloride; 2. naltrexone.
- •Primary use
- •ocular side effects
- •Local ophthalmic use or exposure (naloxone)
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: Strong analgesics
- •Generic name: Diacetylmorphine (diamorphine, heroin).
- •Primary use
- •ocular side effects
- •Systemic administration
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Hydromorphone hydrochloride (dihydromorphinone); 2. oxymorphone hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Methadone hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Morphine; 2. opium.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure – morphine
- •Epidural or intravenous exposure
- •Ocular teratogenic effects
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Pethidine hydrochloride (meperidine).
- •Primary use
- •ocular side effects
- •Systemic administration
- •Inadvertent ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Pentazocine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: adjuncts to anesthesia
- •Generic name: Hyaluronidase.
- •Primary use
- •ocular side effects
- •Subconjunctival or retrobulbar injection
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: 1. Hyoscine (scopolamine); 2. hyoscine methobromide (methscopolamine).
- •Primary use
- •Systemic
- •Topical
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Local ophthalmic use or exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Suxamethonium chloride (succinylcholine).
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •Recommendations for use in open globe (after chidiac 2004)
- •REFERENCES AND FURTHER READING
- •class: General anesthesia
- •Generic name: Ether (anesthetic ether).
- •Primary use
- •ocular side effects
- •Systemic administration
- •Inadvertent ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Ketamine hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Methoxyflurane.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: nitrous oxide.
- •Primary use
- •ocular side effects.
- •Systemic administration
- •Intravitreal injection of gas during vitrectomy
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic name: Propofol.
- •Primary use
- •ocular side effects
- •Intravenous administration
- •Accidental ocular exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: local anesthetics
- •Generic names: 1. Bupivacaine hydrochloride; 2. chloroprocaine hydrochloride; 3. lidocaine; 4. mepivacaine hydrochloride; 5. prilocaine; 6. procaine hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration – spiral, caudal, epidural, extradural injections
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: tHerapeutic Gases
- •Generic name: Carbon dioxide.
- •Primary use
- •ocular side effects
- •Systemic administration – extreme concentrations
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Generic names: Oxygen, oxygen-ozone.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •class: agents used to treat acid Peptic disorders
- •Generic names: 1. Cimetidine; 2. famotidine; 3. nizatidine; 4. ranitidine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •clinical significance
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •generic names: 1. Ergometrine maleate (ergonovine); 2. ergotamine tartrate; 3. methylergometrine maleate (methylergonovine).
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: antianginal agents
- •generic name: 1. Amyl nitrite; 2. butyl nitrite.
- •Primary use
- •ocular side effects
- •Inhalation administration
- •Topical ocular application – inadvertent contact with liquid
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Diltiazem hydrochloride; 2. nifedipine; 3. verapamil hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •generic names: 1. flecainide acetate; 2. procainamide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: nitroglycerin.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: antiarrythmic agents
- •generic name: Amiodarone.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •recommendations
- •REFERENCES AND FURTHER READING
- •generic name: Disopyramide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Methacholine chloride.
- •Primary use
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: 1. Oxprenolol hydrochloride; 2. propranolol hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Quinidine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: antihypertensive agents
- •generic names: 1. Acebutolol; 2. atenolol; 3. carvedilol; 4. labetolol hydrochloride; 5. metoprolol; 6. nadolol; 7. pindolol.
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: 1. Alfuzosin hydrochloride; 2. doxazosin; 3. tamsulosin; 4. terazosin.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Captopril; 2. enalapril.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Clonidine.
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Diazoxide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Guanethidine monosulfate.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Hydralazine hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Minoxidil.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Topical application
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Prazosin hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic names: 1. Rescinnamine; 2. reserpine.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: BronChodilators
- •generic name: Ipratropium.
- •Primary use
- •ocular side effects
- •Systemic administration – solution, aerosols or nasal sprays
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Salbutamol (albuterol).
- •Primary use
- •ocular side effects
- •Systemic administration – nebulizer
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: diuretics
- •generic names: 1. Bendroflumethiazide; 2. chlorothiazide; 3. chlortalidone; 4. hydrochlorothiazide; 5. hydroflumethiazide; 6. indapamide; 7. methyclothiazide; 8. metolazone; 9. polythiazide; 10. trichlormethiazide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: furosemide.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Osmotics
- •generic name: Glycerol (glycerin).
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Mannitol.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Peripheral Vasodilators
- •generic name: Phenoxybenzamine hydrochloride.
- •Primary use
- •ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Class: Vasopressors
- •generic name: Ephedrine.
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: 1. Epinephrine; 2. norepinephrine (levaterenol).
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration – injection
- •Local ophthalmic use or exposure
- •Systemic side effects
- •Local ophthalmic use or exposure – epinephrine
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •generic name: Phenylephrine.
- •Primary use
- •Systemic
- •Ophthalmic
- •ocular side effects
- •Systemic administration – nasal application
- •Local ophthalmic use or exposure
- •Systemic side effects
- •Local ophthalmic use or exposure
- •Conditional/Unclassified
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Intraocular injection
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Systemic
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration (toxic levels)
- •Inadvertent ocular exposure
- •REFERENCES AND FURTHER READING
- •Systemic
- •Ophthalmic
- •Intrathecal and intraventricular injections
- •Intracameral injection
- •Local ophthalmic use or exposure
- •REFERENCES AND FURTHER READING
- •Systemic
- •Ophthalmic
- •Systemic administration – intravenous injections
- •Intracrameral injections
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •Local ophthalmic use or exposure – subconjunctival injection
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration – intravenous
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •Ocular teratogenic effects
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration – oral
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Class: Antihistamines
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Ocular side effects
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •Local ophthalmic use or exposure – mitomycin
- •REFERENCES AND FURTHER READING
- •Systemic administration – intravenous
- •Ocular teratogenic effects
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration – intraveneous
- •Systemic administration – intracarotid injection
- •REFERENCES AND FURTHER READING
- •Systemic administration – intravenous
- •REFERENCES AND FURTHER READING
- •Systemic administration – intravenous
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic
- •Ophthalmic
- •Systemic administration
- •Local ophthalmic use or exposure
- •REFERENCES AND FURTHER READING
- •Systemic administration – intravenous
- •REFERENCES AND FURTHER READING
- •Systemic administration – intracarotid injection
- •REFERENCES AND FURTHER READING
- •Systemic
- •Ophthalmic
- •Systemic administration
- •Injection into the eyelid (fluorouracil)
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration (intramuscular, subcutaneous or intravenous injections)
- •REFERENCES AND FURTHER READING
- •Ocular side effects
- •Systemic administration (interleukin 2)
- •Subcutaneous administration (interleukin 3 and 6)
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •Ocular teratogenic effects
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic administration
- •REFERENCES AND FURTHER READING
- •Systemic
- •Ophthalmic
- •Systemic administration (intravenous, intramuscular)
- •Local ophthalmic use or exposure
- •clinical significance
- •REFERENCES AND FURTHER READING
- •Systemic administration (vincristine unless stated)
- •Inadvertent ocular exposure – vinblastine
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFERENCES AND FURTHER READING
- •REFEREnCEs AnD FuRTHER READInG
- •Chemical-induced ocular side effects
- •Class: acids
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Hydrofluoric acid
- •Hydrochloric acid
- •Sulfuric acid
- •Ocular side effects
- •Direct ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Aerosols
- •Generic names:
- •synonyms:
- •Primary use
- •Ocular side effects
- •Direct ocular exposure
- •Defective or improper delivery – powder form of CS and CN
- •systemic side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •Proprietary name:
- •Primary use
- •Ocular side effects
- •Systemic administration – acute intoxication
- •Systemic administration – chronic intoxication
- •Ocular teratogenic effects (fetal alcohol syndrome)
- •Local ophthalmic use or exposure – retrobulbar injection
- •Inadvertent ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Primary use
- •Ocular side effects
- •Direct ocular exposure
- •Systemic exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Direct ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Systemic exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Direct ocular exposure
- •Systemic exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Alkali
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical Ocular Exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Direct ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Bleaches
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Detergents
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Glues
- •Generic name:
- •synonyms:
- •Proprietary names:
- •Primary use
- •Ocular side effects
- •Topical Ocular Exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Herbicides and insecticides
- •Generic name:
- •synonyms:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic names:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Systemic exposure – acute effects
- •Systemic exposure – chronic effects
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: Hydrocarbons
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Systemic exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Class: MisCellaneOus
- •Generic name:
- •synonyms:
- •Proprietary names/products containing:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Generic name:
- •synonyms:
- •Proprietary names:
- •Primary use
- •Ocular side effects
- •Topical ocular exposure
- •Clinical significance
- •Recommendations
- •REFERENCES AND FURTHER READING
- •Herbal medicine and dietary supplement induced ocular side effects
- •Herbal or supplement name: Canthaxanthine.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Local ophthalmic use or exposure
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Herbal or supplement name: Datura.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Herbal or supplement name: Ginkgo biloba.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Herbal or supplement name: Licorice.
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
- •Herbal or supplement name: Retinol (Vitamin A).
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FuRTHER READING
- •Primary use
- •Ocular side effects
- •Systemic administration
- •Clinical significance
- •REFERENCES AND FURTHER READING
Probable
1. Retinal hemorrhages (caudal block)
2. Macular edema
3. Photosensitivity
Local ophthalmic use or exposure – retrobulbar parabulbar injection (bupivacaine, lidocaine, mepivacaine, procaine)
Certain
1. Decreased or loss of vision – temporary
2. Paresis or paralysis of extraocular muscles, including contralateral 6th nerve (Fig. 7.4c)
3. Decreased intraocular pressure
4. Eyelids or conjunctiva
a.Allergic reactions
b.Hyperemia
c.Blepharoconjunctivitis
d.Edema
e.Urticaria
f.Blepharoclonus
5. Pain – dependent in part on temperature of solution
Possible
1. Eyelids or conjunctiva – exfoliative dermatitis
Conditional/Unclassified
1. Orbital inflammation
Inadvertent topical intraocular injection - anterior or posterior segment
Certain
1. Vision loss
2. Corneal edema
3. Endothelial cell loss
4. Increased intraocular pressure (transitory)
5. Uveitis
6. Hypotony
7. Decreased pupillary function
8. Pigment dispersion syndrome
9. Cataracts
10.Chronic Descemet’s membrane wrinkling
Inadvertent ocular exposure (lidocaine)
Certain
1. Pupils
a.Mydriasis
b.Absence of reaction to light 2. Decreased vision
3. Superficial punctate keratitis
Systemic side effects
Local ophthalmic use or exposure retrobulbar injection
Certain
1. Convulsion
2. Apnea
3. Cardiac arrest
4. Methaemoglobin (prilocaine)
Clinical significance
Spinal, caudal, epidural and extradural injections of local anesthetics rarely cause ocular side effects. The most common ocular adverse event is an extraocular nerve palsy or paralysis. This may start with or without a headache followed by a weakness of the 6th nerve, although the 3rd and 4th nerves may also be involved. This may occur as soon as 2 hours after the spinal injection or up to 3 weeks later. Recovery usually occurs in 3 days to 3 weeks but has required up to 18 months. Acute bilateral central scotomas, possible due to hypotension or macular ischemia,
Fig. 7.4c Results of motility examination 6 months after cataract surgery show a right hypertropia in primary position, increasing to right gaze and decreasing to left gaze. Photo courtesy of Han SK, et al. Persistent diplopia after retrobulbar anesthesia. J Cataract Refract Surg. 30: 1248–1253, 2004.
•anesthesia4 Sectionin used Agents
135
effects side ocular induced-Drug • 7 t Pa r
have been reported. These side effects were more common decades ago when the purity of some products was in doubt or before the detergents used to clean equipment were found to be toxic.
Regional anesthesia has caused ocular adverse events but it is difficult to rule out mechanical (speed of injection, bolus effect, increased local pressure) emboli from a toxic effect. Case reports include diplopia after a dental procedure (Walker et al 2004), bilateral transient blindness during hand surgery (Sawyer et al 2002) and permanent uniocular blindness after a dental extraction (Rishiraj et al 2005).
Adverse events secondary to retrobulbar or peribulbar injections of anesthetics are seldom of clinical importance. However, problems may arise secondary to injections into the optic nerve sheath or nerve itself. Irreversible ischemic changes secondary to pressure effects that impede ocular blood flow, direct toxicity to muscle or needle-induced trauma may occur. Myotoxic effects of local anesthetics, which could cause degeneration and subsequent regeneration of extraocular muscles, could explain some cases of postoperative diplopia and ptosis. Han et al (2004) state that persistent diplopia post-retrobulbar anesthesia is due to drug myotoxicity or from direct trauma. Transient loss of vision is practically routine from retrobulbar injections of lidocaine or procaine. There have been occasional reports of cardiopulmonary arrest or grand mal seizures following the retrobulbar administration of bupivacaine, lidocaine, mepivacaine or procaine. Warming the anesthetic prior to injection was found by Ursell and Spalton (1996) to decrease the iatrogenic pain of the injection.
Inadvertent intraocular injection of a local anesthetic into the anterior chamber is a rare but potentially devastating event. Instances of toxicity to the corneal endothelial cell secondary to local anesthesia have recently increased due to the use of intra cameral anesthesia. Judge et al (1997) has reviewed this in animals. Shah et al (2004), along with others, point out that if one uses preservative-free 1% xylocaine (lidocaine), the endothelium is not adversely affected during phacoemulsification. Eggeling et al (2000) concur that lidocaine at 1% appears safe. Dance et al (2005) point out that some patients allergic to ‘caines’ do not react adversely to preservative-free lidocaine. Lee et al (2003) confirm that intracameral 1% lidocaine causes pupillary dilation in the eyes, which are difficult to dilate. Higher concentrations of local anesthetics are toxic to the lens and cornea epithelium.
Inadvertent intraocular injection of lidocaine has been reported to cause cataracts. Pigment dispersion is common, and much of this may be mechanical due to the fire hose effect of a fluid under pressure being forced out through a small gauge needle. The resultant stream has a shearing effect on the tissue it comes into contact with. Pupillary function is often decreased and even absent, partially due to acute secondary glaucoma, synechiae or a direct drug effect. The spectrum of injury is broad; however, if the posterior segment is not involved and chronic glaucoma is avoided, the prognosis may be good with corneal surgery. The outcome of inadvertent local anesthetic injected in the posterior segment is often dependent on the direct effect of the penetration trauma. Although a double perforation may have a better prognosis than a single perforation, an injection through the pars plana may be devoid of significant effects other than the acute rise in intraocular pressure. The immediate effect of the injection is a marked increase in intraocular pressure, with or without pupillary dilation, corneal edema or loss of vision. All of the above are transitory since there appear to be no significant long-term toxic effects of the local anesthetic on the retina or optic nerve. The chief concern is control of the acute rise in pressure, which may be severe enough to cause central retinal
venous or arterial occlusion. Next are the problems from retinal perforation, vitreous adhesion or retinal detachment. Lemagne et al (1990) reported a case of Purtscher-like retinopathy with a retrobulbar injection of a local anesthetic. The exudates and hemorrhages disappeared while a localized paracentral scotoma and afferent pupillary defect were permanent.
Numerous systemic reactions from topical ocular applications of local anesthetics have been reported. Many of these occur in part from the fear of the impending procedure or possibly an oculocardiac reflex. Side effects reported include syncope, convulsions and anaphylactic shock.
Local anesthetics applied to the eye are seldom of importance except with multiple repeat exposures.
References and Further Reading
Anderson NJ, Woods WD, Terry K, et al. Intracameral anesthesia. Arch Ophthalmol 117: 225–232, 1999.
Antoszyk AN, Buckley EG. Contralateral decreased visual acuity and extraocular palsies following retrobulbar anesthesia. Ophthalmology 93: 462, 1986.
Breslin CW, Nershenfeld S, Motolko M. Effect of retrobulbar anesthesia on ocular tension. Can J Ophthalmol 18: 223, 1983.
Carruthers JDA, Sanmugasunderan S, Mills K, et al. The efficacy of topical corneal anesthesia with 0.5% bupivacaine eyedrops. Can J Ophthalmol 30(5): 264–266, 1995.
Cohen RG, Hartstein M, Ladav M, et al. Ocular toxicity following topical application of anesthetic cream to the eyelid skin. Ophthalmic Surg Lasers 27: 374–377, 1996.
Dance D, Basti S, Koch DD. Use of preservative-free lidocaine for cataract surgery in a patient allergic to ‘caines’. J Cataract Refract Surg 31: 848–850, 2005.
Duker JS, et al. Inadvertent globe perforation during retrobulbar and peribulbar anesthesia. Patient characteristics, surgical management, and visual outcome. Ophthalmology 98(4): 519–526, 1991.
Eggeling P, Pleyer U, Hartmann C, et al. Corneal endothelial toxicity of different lidocaine concentrations. J Cataract Refract Surg 6: 1403–1408, 2000.
Eltzschig H, Rohrbach M, Hans Schroeder T. Methaemoglobinaemia after peribulbar blockade: An unusual complication in ophthalmic surgery. Br J Ophthalmol 84: 439, 2000.
Gild WM, et al. Eye injuries associated with anesthesia. A closed claims analysis. Anesthesiology 76: 204–208, 1992.
Gills JP. Effect of lidocaine on lens epithelial cells. J Cataract Refract Surg 30: 1152–1153, 2004.
Haddad R. Fibrinous iritis due to oxybuprocaine. Br J Ophthalmol 73: 76–77, 1989.
Han SK, Kim JH, Hwang J-M. Persistent diplopia after retrobulbar anesthesia. J Cataract Refract Surg 30: 1248–1253, 2004.
Judge AJ, Najafi K, Lee DA, et al. Corneal endothelial toxicity of topical anesthesia. Ophthalmology 104: 1373–1379, 1997.
Kim T, Holley GP, Lee JH, et al. The effects of intraocular lidocaine on the corneal endothelium. Ophthalmology 105(1): 125–130, 1998.
Lee JJ, Moster MR, Henderer JD, et al. Pupil dilation with intracameral 1% lidocaine during glaucoma filtering surgery. Am J Ophthalmol 136: 201–203, 2003.
Lemagne JM, et al. Purtscher-like retinopathy after retrobulbar anesthesia. Ophthalmology 97(7): 859–861, 1990.
Lincoff N, et al. Intraocular injection of lidocaine. Ophthalmology 92: 1587, 1985.
Meyer D, Hamilton RC, Gimbel HV. Myasthenia gravis-like syndrome induced by topical ophthalmic preparations. A case report. J Clin Neuro-ophthalmol 12(3): 210–212, 1992.
Mukherji S, Esakowitz L. Orbital inflammation after sub-tenon’s anesthesia. J Cataract Refract Surg 31: 2221–2223, 2005.
Rishiraj B, Epstein JB, Fine D, et al. Permanent vision loss in one eye following administration of local anesthesia for a dental extraction. Int J Oral Maxillofac Surg 34: 220–223, 2005.
Salama H, Farr AK, Guyton DL. Anesthetic myotoxicity as a cause of restric tive strabismus after scleral buckling surgery. Retina 20: 478–482, 2000.
Sawyer RJ, von Schroeder H. Temporary bilateral blindness after acute lidocaine toxicity. Anesth Analg 95: 224–226, 2002.
Shah AR, Diwan RP, Vasavada AR, et al. Corneal endothelial safety of intracameral preservative-free 1% xylocaine. Indian J Ophthalmol 52: 133–138, 2004.
136
